glp 1 agonist therapy GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Evolution of GLP‐1 Receptor Agonists

MON-681 dulaglutide commonly known as trulicity

30 A total of 711 patients with T2DM (mean baseline A1C of approximately 8% in all treatment groups) were enrolled and randomized to receive one of three interventions: 1) 14 mg daily of oral semaglutide

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

The Swedish Obesity Subjects Study from 2007 evaluated over 4,000 patients in a prospective matched control study and demonstrated improvements in mortality, mostly due to reduction in death from cancer and myocardial infarction, of up to 2030% based on the degree of obesity prior to surgery with sustained outcomes at 1015 years of follow-up [21]

39 However, this study did not control for relevant risk factors such as smoking, blood pressure, and body mass index

[DOI] [PMC free article] [PubMed] [Google Scholar] 17.Zaletel J., Barlovic D.P., Prezelj J